Benzinga · Mar 5, 2026
B. Riley Securities Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18
B. Riley Securities analyst Neil Chatterji maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $28 to $18.
CL
NASDAQ · CLPT
ClearPoint Neuro, Inc.
Healthcare · Medical - Devices
$10.67
Down-$0.02 (-0.19%)
Updated Nov 2, 2026, 3:42 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 368.85M
- P/E ratio
- -16.51
- Dividend yield
- 0.00%
- 52-week range
- $8.27 – $24.98
- Volume
- 916.51K
- Avg. volume
- 1.09M
Price performance · CLPT
CLPT price history
1M range · 0 trading sessions · Daily adjusted prices
CLPT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CLPT news
The latest Smart Investors Daily articles mentioning CLPT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CLPT research
Overview
Company profile and research snapshot.
Company profile
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $18.00
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Stifel | Buy | — |
| Jun 18, 2026 | B. Riley Securities | Buy | — |
| Mar 18, 2026 | B. Riley Securities | Buy | — |
| Mar 5, 2026 | B. Riley Securities | Buy | — |
| Aug 1, 2025 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Jan 27, 2026
CLPT Gets EU MDR Certification for ClearPoint Navigation Software
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
SeekingAlpha · Jan 27, 2026
ClearPoint Neuro: From Validation To Scale
ClearPoint Neuro outlook for 2026: IRRAS, PRISM 1.5T clearance & new CRO facility could drive growth. Learn more about CLPT stock here.
Yahoo · Jan 22, 2026
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
